314O_PR Second-line afatinib vs methotrexate (MTX) in patients (pts) with recurrent and/or metastatic head and neck squamous cell carcinoma (R/M HNSCC): subgroup/biomarker analysis of LUX-head and neck 1 (LUX-H&N1)
Year: 2015
Type: article
Source: Annals of Oncology
Institutions: National Cancer Center Hospital East, Moores Cancer Center, Brigham and Women's Hospital, Harvard University, Dana-Farber Cancer Institute, Dana-Farber Brigham Cancer Center, Hospices Civils de Lyon, Fondazione IRCCS Istituto Nazionale dei Tumori, KU Leuven, Antwerp University Hospital, Essen University Hospital, Hospital Clínic de Barcelona, Universitat de Barcelona, Institut Gustave Roussy, Centre Antoine Lacassagne, Vall d'Hebron Hospital Universitari, Tokai University Hospital, Japanese Foundation For Cancer Research, Fox Chase Cancer Center, Boehringer Ingelheim (United States), Boehringer Ingelheim (Germany), Boehringer Ingelheim (Austria), Boehringer Ingelheim (Denmark), Cliniques Universitaires Saint-Luc, UCLouvain
Language: English
Topic: Head and Neck Cancer Studies
Subfield: Otorhinolaryngology
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W2323729627